EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Strong immunogenicity and protection against SARS-CoV-2 in hamsters induced by heterologous boost vaccination with an MVA-based COVID-19 vaccine candidate

Sonja Ohrnberger, Christian Meyer Zu Natrup, Sabrina Clever, Lisa-Marie Schünemann, Federico Armando, Malgorzata Ciurkiewicz, Wolfgang Baumgärtner, Georgia Kalodimou, Gerd Sutter, Alina Tscherne, Asisa Volz

Journal of General Virology · 2025

DOI: 10.1099/jgv.0.002180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of General Virology, 2025. Verfasst von Sonja Ohrnberger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Virology, University of Veterinary Medicine Hannover, 30559 Hanover, Germany. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, COVID-19 Vaccines, Immunogenicity, Vaccine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsches Zentrum für Infektionsforschung, Niedersächsische Ministerium für Wissenschaft und Kultur, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the last decade, heterologous prime–boost vaccination regimens have been established as a promising strategy to enhance immune responses and make optimal use of the advantages of different vaccine platforms. Modified vaccinia virus Ankara (MVA), a replication-deficient poxviral vector with an established safety profile, is under clinical investigation as a versatile recombinant vaccine platform against various infectious diseases. In the context of coronavirus disease 2019 (COVID-19), a recombinant MVA-based vaccine candidate expressing the prefusion-stabilized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (MVA-ST) has demonstrated safety, immunogenicity and protection in preclinical studies using different animal models. Furthermore, a phase Ib clinical trial in healthy adults showed that MVA-ST is safe, well-tolerated and immunogenic when used as a booster following mRNA priming. In this study, we evaluated heterologous prime–boost vaccination regimens using MVA-ST as a booster in Syrian hamsters. Hamsters were primed with an mRNA vaccine (BNT162b2, BioNTech/Pfizer) or the adenoviral vector vaccine Ad26.COV2.S (Janssen) and subsequently boosted with MVA-ST at a dose of 10⁸ p.f.u. These heterologous vaccination regimens induced robust protection against severe SARS-CoV-2 disease, with superior immunogenicity compared to homologous MVA-ST vaccination. Notably, even a lower booster dose (10⁷ p.f.u.) of MVA-ST following mRNA priming conferred strong protection against SARS-CoV-2 challenge infection, while still associated with limited viral shedding from the upper respiratory tract. These findings highlight the potential of MVA-ST as a heterologous booster to enhance the immunogenicity and protective efficacy of existing COVID-19 vaccines and also to improve vaccination strategies against other emerging pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19COVID-19 VaccinesImmunogenicity, VaccineAnimalsImmunization, SecondaryCricetinaeAntibodies, ViralVaccinia virusMesocricetusSpike Glycoprotein, CoronavirusFemaleVaccinationBNT162 VaccineVaccines, SyntheticAntibodies, NeutralizingHumansMaleDisease Models, Animal

Stichwörter der Autor:innen

emerging virusesheterologous vaccinationlow-dose vaccinationmodified vaccinia virus Ankarasevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Substanzen

COVID-19 VaccinesAntibodies, ViralSpike Glycoprotein, CoronavirusBNT162 VaccineVaccines, SyntheticAntibodies, Neutralizingspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Institute of Virology, University of Veterinary Medicine Hannover, 30559 Hanover, Germany.
  • Department of Pathology, University of Veterinary Medicine Hannover, 30559 Hanover, Germany.
  • Division of Virology, Department of Veterinary Sciences, Ludwig Maximilians University (LMU Munich), 85764 Oberschleißheim, Germany.

Förderung

  • Deutsches Zentrum für Infektionsforschung
  • Niedersächsische Ministerium für Wissenschaft und Kultur
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Ohrnberger, S., Meyer Zu Natrup, C., Clever, S., Schünemann, L. M., Armando, F., Ciurkiewicz, M., Baumgärtner, W., Kalodimou, G., Sutter, G., Tscherne, A., & Volz, A. (2025). Strong immunogenicity and protection against SARS-CoV-2 in hamsters induced by heterologous boost vaccination with an MVA-based COVID-19 vaccine candidate. Journal of General Virology. https://doi.org/10.1099/jgv.0.002180

Vancouver

Ohrnberger S, Meyer Zu Natrup C, Clever S, Schünemann LM, Armando F, Ciurkiewicz M, et al. Strong immunogenicity and protection against SARS-CoV-2 in hamsters induced by heterologous boost vaccination with an MVA-based COVID-19 vaccine candidate. Journal of General Virology. 2025. doi:10.1099/jgv.0.002180

BibTeX
@article{Ohrnberger2025,
  author = {Ohrnberger, Sonja and Meyer Zu Natrup, Christian and Clever, Sabrina and Schünemann, Lisa-Marie and Armando, Federico and Ciurkiewicz, Malgorzata and Baumgärtner, Wolfgang and Kalodimou, Georgia and Sutter, Gerd and Tscherne, Alina and Volz, Asisa},
  title = {Strong immunogenicity and protection against SARS-CoV-2 in hamsters induced by heterologous boost vaccination with an MVA-based COVID-19 vaccine candidate},
  journal = {Journal of General Virology},
  year = {2025},
  doi = {10.1099/jgv.0.002180}
}
Kostenlos starten →